India, July 2 -- Insilico Medicine (3696.HK), a clinical-stage company specializing in generative AI for drug discovery, has entered into a strategic collaboration with Takeda Pharmaceutical Company Ltd. (TSE:4502) to advance novel drug candidates across Takeda's therapeutic areas.
The partnership will leverage Insilico's proprietary end-to-end platform, Pharma.AI, to identify clinically differentiated drug candidates for promising therapeutic targets. By applying advanced generative models from the earliest stages of design, the collaboration aims to improve molecule quality and optimize candidates for best-in-class efficacy and safety.
Under the agreement, Insilico will lead AI-driven discovery to identify molecules meeting predefined s...